Preimplantation Genetic Testing Market - A Global and Regional Analysis: Focus on Product, Application, Technology, End User, Country Data (15 Countries) - Analysis and Forecast, 2021-2031

Market Overview

Preimplantation genetic diagnosis (PGD) is performed among couples that have a higher risk of transmitting a genetic condition to their offspring. The technique is employed in in-vitro fertilization centers globally to select the euploid embryos to transfer and improve the clinical outcome of the clinical pregnancy, embryo implantation, and live birth rates. The ability to identify the preimplantation embryos with the genetic defects prior to the initiation of the pregnancy also offers an attractive alternative to chorionic villous sampling or amniocentesis.

The preimplantation genetic testing is set to grow at a significant rate in the upcoming years as the technology and awareness regarding the test improve.

The global preimplantation genetic testing market was valued at $972.1 million in 2020 and is expected to reach $2,725.7 million by 2031, registering a CAGR of 9.69% during the forecast period 2021-2031.

The growth is attributed to the advancing maternal age globally, rising adoption of in-vitro fertilization, increasing awareness of genetic testing, and rising emphasis on predictive testing. Further, continued significant investments by biotechnology firms to improve the technology for genetic testing and to improve affordability have also promoted the prominence of preimplantation genetic testing.

Within the research report, the market is segmented based on product, application, end user, technology, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the usage of in-vitro fertilization facilities as an option for healthy childbirth and increasing affordability for genetic testing on a global level has created awareness as well as demand among consumers, which has eventually led to the companies to invest in the development of more such preimplantation genetic test. The companies such as Agilent Technologies, Inc. and Natera, Inc. have been incorporating major strategies to enhance their market presence via key developments. The other major contributors to the market include companies such as Thermo Fisher Scientific, PerkinElmer, Inc., Invitae Inc., and Igenomix.

Based on region, North America holds the largest share of the preimplantation genetic testing market due to eased regulatory scenario and a large number of IVF facilities offering such PGT tests. Further, substantial investments made by biotechnology companies to improve the genetic testing facilities and advancing technologies along with the rise in per capita income in the region are also fuelling the growth of the respective market. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

BIS Research is a global B2B market intelligence and advisory firm focusing on those emerging technological trends which are likely to disrupt the dynamics of the market.

With over 150 market research reports published annually, BIS Research focuses on high technology verticals such as 3D Printing, Advanced Materials and Chemicals, Aerospace and Defense, Automotive, Healthcare, Electronics and Semiconductors, Robotics and UAV, and other emerging technologies.

Our in-depth market intelligence reports focus on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.